[Influence of circulatory dysfunction on the treatment of ascites and hepatorenal syndrome: vasoconstrictor and diuretic drug treatment].
Torre
A
A
Servei d'Hepatologia, Institut de Malalties Digestives, Hospital Clínic de Barcelona, Instituto Reina Sofía de Investigación Neurológica, Institut d'Investigacions Biomèdiques August Pi-Sunyer (IDIBAPS), Universitat de Barcelona.
Terra
C
C
Guevara
M
M
Ginès
P
P
D065092:Antidiuretic Hormone Receptor Antagonists; D001201:Ascites / Q000209:etiology / Q000628:therapy*; D004232:Diuretics / Q000627:therapeutic use*; D004487:Edema / Q000209:etiology; D006530:Hepatorenal Syndrome / Q000188:drug therapy / Q000503:physiopathology / Q000628:therapy*; D006801:Humans; D007010:Hyponatremia / Q000209:etiology* / Q000503:physiopathology / Q000628:therapy; D007668:Kidney / Q000503:physiopathology; D008103:Liver Cirrhosis / Q000150:complications* / Q000503:physiopathology; D016031:Liver Transplantation; D011170:Portasystemic Shunt, Surgical; D006435:Renal Dialysis; D014662:Vasoconstrictor Agents / Q000627:therapeutic use*; D014664:Vasodilation / Q000187:drug effects
D065092:Antidiuretic Hormone Receptor Antagonists; D004232:Diuretics; D014662:Vasoconstrictor Agents